Fig. 5From: The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysisForest plot for the weighted-pooled proportions of adverse events in patients receiving sirolimus or everolimus including the 95% confidence interval from random effect model and number of included study(n)Back to article page